Every Billion-Dollar China Oncology Deal Just Got Harder
FDA rejection of Summit’s ivonescimab tests the case for in-licensed Chinese cancer drugs.
FDA rejection of Summit’s ivonescimab tests the case for in-licensed Chinese cancer drugs.
A note from our friends at Base Camp Trading(ad) Hey Trader, This certainly isn’t going to win me any friends…
A claimed Iranian strike on a Gulf state hosting U.S. forces barely registered in oil, and the reason matters more than the attack itself.
ChatGPT Wallet routes purchases through card networks, not around them.
Revenue up 61%, orders doubled, 31 analysts say Strong Buy. The data doesn’t show a bust.
Revenue up 53%, free cash flow of $2.6 billion in a quarter, and Q1 guidance above estimates. The gap between this business and its stock price is the opportunity.
Record profit, a 19.3% efficiency ratio, and a new U.S. business make NU a standout in fintech right now.
A note from our friends at Weiss Ratings(ad) Dear Reader, This is an urgent warning for All American investors ……
Modine Manufacturing closed Thursday at $106.10 and finished Friday around $135, up nearly 28% on the session. The catalyst: Bloomberg…
With the dollar at a 19-month high and the 10-year yield above 5.1%, the sell-off is coming from macro, not crypto.